HIGHBuilt-inPipeline
lead product candidates (cema-cel, ALLO-316, ALLO-329)
“10-K Item 1A: 'Our business is highly dependent on the success of our lead product candidates.'”
ALLO · Concentration risk · 10-K extracted
Allogene Therapeutics (ALLO) concentration risks
Updated
The most significant concentration Allogene Therapeutics discloses is lead product candidates (cema-cel, ALLO-316, ALLO-329), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Allogene Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Allogene Therapeutics discloses a single but significant concentration: the company's business is highly dependent on the success of its lead product candidates — cema-cel, ALLO-316, and ALLO-329. This is a structural, high-share exposure rather than a one-off dependency, reflecting the nature of a clinical-stage cell-therapy company whose value is built around a defined set of pipeline assets rather than a diversified commercial portfolio. Because the disclosure spans three named candidates rather than one, there is some internal spread — a setback in a single program does not necessarily sink the whole platform — but the filing still frames overall success as contingent on this group succeeding together. There are no customer, supplier, or geographic concentrations disclosed here to offset or compound this exposure, so the pipeline dependency is effectively the whole story for now. The investment verdict is therefore highly sensitive to clinical and regulatory catalysts for these three candidates, with data readouts representing the key events that could move sentiment in either direction.
For the engine’s reasoning on ALLO’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ALLO● | Allogene Therapeutics, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.